LONDON, UK — Prolonging the infusion of bivalirudin (Angiomax/Angiox, the Medicines Company) for several hours after the completion of PCI did not reduce the composite outcome of ischemic and bleeding ...

Patients with acute coronary syndrome undergoing angioplasty who received the anticoagulant drug bivalirudin did not show significant improvements in either of two co-primary endpoints--a composite of ...

Please provide your email address to receive an email when new articles are posted on . Among patients with ACS who received an infusion of bivalirudin after PCI, those who had a full dose showed ...

MUNICH, Germany—Long-term follow-up from the Minimizing Adverse Hemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX) trial confirm the results observed at 30 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. MUNICH — At 1 year, a strategy of transradial access for ...

WILMINGTON, N.C.--(BUSINESS WIRE)--The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, and Matrix Clinical Trials, a Matrix Medical Network ...

"At the onset of the pandemic Matrix mobilized quickly to provide decentralized clinical trial solutions in support of vaccine and therapy development for COVID-19. We leveraged our skilled clinicians ...